Specialty pharmaceutical company iX Biopharma has obtained export listing status for Xativa, its CBD (cannabidiol) sublingual wafer.
In a press release on June 28, iX Biopharma announced Xativa’s inclusion in the Australian Register of Therapeutic Goods' (ARTG) list of drugs approved for export.
Pursuant to the approval, the company will commence supply of Xativa to Brazil, where it will distribute and market the product through local partners.
See also: Broker's Digest: Venture Corp, Grand Venture Technology, Sasseur REIT, iX Biopharma, SGX
Available in 12.5mg and 25mg doses, Xativa is the world’s first sublingual medicinal cannabis wafer developed using iX Biopharma’s patented WaferiX sublingual delivery technology.
“Obtaining export listing for Xativa is a significant milestone. It brings us closer to realizing our ambition of becoming a medicinal cannabis supplier to global markets. This positive development follows the timely expansion of our wafer production capacity, which will support our entry into the Brazil and other international markets. We expect to benefit from the sustained and dynamic growth in Brazil and are confident that this move will position us competitively to expand our footprint in markets beyond Australia,” says Eva Tan, chief commercial officer of iX Biopharma.
Apart from Brazil, iX Biopharma says it is also pursuing partnerships with companies and distributors in other markets.
Currently, the company supplies Xativa to patients with medical prescriptions in Australia via the Special Access Scheme and Authorised Prescriber Scheme.
As at 9.06am, shares in iX Biopharma are up 1 cent or 4.26% higher at 24.5 cents.
Photo: Bloomberg
